SCHEMBL4124263

SCHEMBL4124263

COc1cccc([C@@H]2S[C@@H](CC(=O)OC(C)C)C(=S)Nc3ccc(Cl)cc32)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDYL2 Q8N8U2 1/20 0.39
CDYL Q9Y232 1/20 0.39
EGFR P00533 1/20 0.36
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
FDFT1 P37268 5/20 0.33
MAPT P10636 4/20 0.33
ALDH1A1 P00352 1/20 0.33
PKM P14618 1/20 0.33
MAPK1 P28482 1/20 0.33
LPAR1 Q92633 1/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2C9 P11712 2/20 0.32
TSHR P16473 2/20 0.32
CYP2C19 P33261 2/20 0.32
TP53 P04637 1/20 0.32
ALOX15 P16050 1/20 0.32
CASP1 P29466 1/20 0.32
RECQL P46063 1/20 0.32
SLC8B1 Q6J4K2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4124269 1.00 CDYL2 (0.39) CDYL2CDYLEGFRMEN1KMT2A
SCHEMBL4124266 1.00 CDYL2 (0.39) CDYL2CDYLEGFRMEN1KMT2A
SCHEMBL4117973 0.93 EGFR (0.39) CDYL2CDYLEGFRMEN1KMT2A
SCHEMBL4117976 0.93 EGFR (0.39) CDYL2CDYLEGFRMEN1KMT2A
SCHEMBL4117966 0.93 EGFR (0.39) CDYL2CDYLEGFRMEN1KMT2A
SCHEMBL4127940 0.92 CDYL2 (0.39) CDYL2CDYLEGFRFDFT1TSHR
SCHEMBL4127942 0.92 CDYL2 (0.39) CDYL2CDYLEGFRFDFT1TSHR
SCHEMBL4117250 0.92 CDYL2 (0.39) CDYL2CDYLEGFRMEN1KMT2A
SCHEMBL4118944 0.92 CDYL2 (0.39) CDYL2CDYLEGFRFDFT1TSHR
SCHEMBL4117246 0.92 CDYL2 (0.39) CDYL2CDYLEGFRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR CDYL2 1908/4885CDYL 1152/4885EGFR 3943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.